Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BenQ Medical Technology's revenue for the
three
months ended in Jun. 2026 was NT$1,429 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$5,445 Mil.
BenQ Medical Technology's Revenue per Share for the
three
months ended in Jun. 2026 was NT$31.99.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$121.55.
Warning Sign:
BenQ Medical Technology Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of BenQ Medical Technology was 6.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 33.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 21.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BenQ Medical Technology's highest 3-Year average Revenue per Share Growth Rate was 48.00% per year. The lowest was -4.10% per year. And the median was 10.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BenQ Medical Technology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BenQ Medical Technology Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BenQ Medical Technology's Revenue distribution charts can be found below:
* The bar in red indicates where BenQ Medical Technology's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5,445 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BenQ Medical Technology (ROCO:4116) has a Revenue of NT$5,445 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BenQ Medical Technology and its competitors.
Is BenQ Medical Technology's Revenue too high?
BenQ Medical Technology's current Revenue is NT$5,445 Mil. Overall, BenQ Medical Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's Revenue compare to ISRG and BDX?
BenQ Medical Technology's Revenue of NT$5,445 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BenQ Medical Technology and its competitors. BenQ Medical Technology's current Revenue is NT$5,445 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$55.08, compared to a current price of NT$39.35 — trading 28.6% below its estimated fair value. The current Revenue is NT$5,445 Mil. BenQ Medical Technology's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current Revenue is NT$5,445 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?
Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued.
The current stock price of NT$39.35 is trading 28.6% below its estimated GF Value™ of NT$55.08.
GuruFocus considers BenQ Medical Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4116:
Revenue: NT$5,445 Mil
GF Value™: NT$55.08 vs. price of NT$39.35 (28.6% below fair value)
No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
86GF Score
Get the complete analysis for ROCO:4116
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4116 has been successfully added to your 
